The Depo-Provera Cases Hinge on One Question First

The Depo-Provera litigation is one of the fastest-growing mass torts in the country right now, and if you're trying to make sense of it, most of what you'll find online is a firm asking whether you qualify. This isn't that. It's a neutral map of where the cases stand, with the one thing that matters most pulled to the front: before any of these claims sees a jury, the plaintiffs have to win a fight about science. If they lose that fight, the rest may not happen at all.

Here's how it's shaped up.

What the lawsuits claim

Depo-Provera is an injectable contraceptive, a shot of medroxyprogesterone acetate given every few months, on the market since the early nineties and used by tens of millions of women. The lawsuits, filed against Pfizer and related manufacturers, allege the companies knew or should have known that long-term use raised the risk of meningioma, a type of brain tumor, and failed to warn patients and doctors about it. Plaintiffs say that if they'd known, they'd have chosen differently. Pfizer maintains the drug is safe and has fought the claims, including arguing that federal regulation shields it from these suits.

A meningioma is usually not cancer, but that doesn't make it minor. These tumors grow against the brain or spinal cord, and treating them can mean brain surgery and a lifetime of monitoring. The injuries in these complaints are serious.

The event that changed the litigation

For years the science sat in an awkward place: studies suggested a link, the label didn't warn of it, and the lawsuits were scattered. Then, in December 2025, the FDA approved a label change for Depo-Provera adding a warning about the risk of intracranial meningioma with long-term use, and recommending that patients diagnosed with one stop the drug.

That regulatory move was a turning point, and you can see it in the filing numbers. Cases multiplied through late 2025 and into 2026. The label change doesn't decide any lawsuit, but it's exactly the kind of development plaintiffs point to, an official acknowledgment of the risk they say should have been disclosed years earlier. You can read the agency's reasoning in the FDA's drug safety resources. It also complicates one of Pfizer's defenses, since the company had argued the FDA's earlier reluctance to require a warning protected it.

Where it's consolidated

The federal cases were centralized into MDL 3140 in the U.S. District Court for the Northern District of Florida, before Judge M. Casey Rodgers. As with any MDL, this isn't a class action. Each woman's case remains her own; they're pooled so one court can manage the shared discovery and the common scientific questions efficiently. By spring 2026 the MDL held thousands of pending cases, with one source counting well over 3,700 and climbing fast, including a sharp month-over-month jump earlier in the year. There's also a parallel set of cases moving through state courts, particularly in Delaware.

There was even a venue fight before it landed in Florida, with the defendants wanting it in New York and plaintiffs pushing for California. That's normal early-MDL positioning, both sides angling for the forum they think favors them.

The hurdle that comes before everything: general causation

Now the part that actually controls the litigation's fate. Before these cases can move toward trials, the plaintiffs have to establish what's called general causation, the threshold scientific showing that Depo-Provera is even capable of causing meningioma in the first place.

This matters because it's binary and it's early. The court holds hearings on the expert testimony, the defense challenges whether the plaintiffs' scientific experts are reliable enough to put in front of a jury, and the judge acts as a gatekeeper. If the plaintiffs clear it, the litigation rolls forward toward trials. If they don't, if the judge decides the science doesn't support a jury even hearing that the drug can cause these tumors, the whole MDL can stall or collapse regardless of how sympathetic the individual stories are. Briefing and hearings on exactly this question were scheduled across the first half of 2026. It's the gate, and everything downstream waits on it.

The pilot trials and what they'd do

Assuming the science clears, the court lined up a set of early "pilot" cases, the Depo-Provera version of bellwether trials, with the first set to begin in December 2026. Same logic as any MDL test trial: try a few representative cases, watch how juries respond, and let those results inform whether and how the litigation resolves. The pilot verdicts won't bind the other thousands of cases, but they'd put real numbers and real jury reactions on the table, which is usually what moves a mass tort toward a global resolution or toward a long grind of individual trials.

There's also Pfizer's pending motion to dismiss on federal preemption grounds, essentially the argument that because the drug's labeling fell under FDA authority, the failure-to-warn claims can't proceed. A ruling on that could reshape the whole thing on its own, independent of the causation science.

The honest bottom line

If you're watching this litigation, here's the realistic frame. It's large and growing. The December 2025 label change gave it momentum. But it has two big gates ahead of any payout: the general-causation ruling on the science, and Pfizer's preemption motion, either of which could narrow or end it. The first trial isn't until December 2026 at the earliest, and no settlement framework exists yet.

One practical note that isn't legal advice, just a fact about these cases: statutes of limitations in some states run short, occasionally as little as a year from diagnosis or from when the link reasonably should have been known. The timing rules are genuinely state-specific. We'll update this as the causation hearings produce rulings, because that's the domino the rest of the litigation is stacked behind.